Federal Agency Bets $9.5M on AI That Manages Heart Patients Without Human Oversight
Tempus AI wins ARPA-H funding to build autonomous agent that coordinates cardiovascular care, medication, and monitoring for 6 million Americans with heart failure.
Tempus AI Bets Big on Whole-Genome Data as Stock Surges Despite Path to Profitability Remains Unclear
The precision medicine company's ambitious plan to scale from 100,000 to one million genomes by 2027 sent shares soaring 31.9%, even as analysts question whether massive datasets can overcome current $254 million losses.
Federal Agency Bets $62.7 Million on Autonomous AI to Replace Missing Cardiologists
ARPA-H awards contracts to six teams racing to build the first FDA-authorized AI agent that can independently manage heart failure patients around the clock.
FDA Greenlights Tempus AI's Heart Disease Detector as Wall Street Wrestles With 72-Point Valuation Gap
New cardiovascular AI clearance arrives amid stark disagreement over whether the healthcare data platform is deeply undervalued or wildly overpriced.
AI Algorithm Detects Hidden Heart Disease From Routine ECG Readings After FDA Green Light
Tempus AI's newly cleared diagnostic tool identifies pulmonary hypertension in symptomatic patients using standard electrocardiograms, expanding AI-driven cardiovascular screening beyond specialty centers.
Tempus AI Stock Surges Nearly 19% on Strategic Companion Diagnostics Partnership
The healthcare AI company's integration with CellCarta's commercialization network aims to bridge the gap between FDA approval and real-world clinical deployment for cancer diagnostics.
Blood Test Meets AI Platform: New Partnership Aims to Close Alzheimer's Diagnostic Gap for Millions
Lucent Diagnostics and Tempus AI integrate blood-based biomarker testing into EHR workflows, targeting the vast majority of Alzheimer's patients never evaluated for treatment eligibility.
Tempus AI Bets $1.5 Billion on Genomics Consolidation to Dominate Precision Oncology Market
Chicago-based diagnostics giant acquires Personalis in all-stock deal, merging AI-powered multimodal platforms with deep tumor sequencing to create end-to-end cancer profiling powerhouse.
Diagnostic Giant Labcorp Enters AI Drug Discovery Race With Decades of Patient Data as Secret Weapon
Laboratory testing leader leverages billions of clinical test results spanning years to challenge specialized AI drug discovery firms and reshape pharmaceutical research.
AI Pathology Tool Catches Diagnostic Errors in 5% of Prostate Biopsies in Major NHS Trial
Real-world study across three UK health trusts shows Tempus's AI software reduced turnaround times by nearly a day while prompting clinically significant diagnostic changes in over 1% of cases.
What Healthcare AI Can Learn From Vertical AI in Construction
The health AI industry's most durable companies will be those that go deepest in a single clinical domain — not the ones that build the most general-purpose platform. The success of vertical AI in adjacent industries offers a clear template.